Comparison of angiogenic and anti-angiogenic factors in maternal and umbilical cord blood in early- and late-onset pre-eclampsia

Gynecological Endocrinology

Volumn 28, Issue 8, 2012, Pages 628-632

  Sezer, Selda Demircan ^a   Küçük, Mert ^a   Yenisey, Çìdem ^a   Yüksel, Hasan ^a   Odabaşi, Ali Riza ^a   Türkmen, Münevver Kaynak ^a   Çetinkaya Çakmak, Bilin ^b   Ömürlü, Imran Kurt ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b Adnan Menderes University ^*  (Turkey)

Author keywords

angiogenic factors; Early onset pre eclampsia; late onset pre eclampsia; PIGF; sEng; sFlt 1; umbilical cord; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE MEASUREMENT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL BLOOD; ONSET AGE; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; UMBILICAL CORD BLOOD;

ADULT; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; FETAL BLOOD; HUMANS; MEMBRANE PROTEINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TURKEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84863881024     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.650759     Document Type: Article

References (36)

1. Bdolah Y, Karumanchi SA, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J 2005;46:728-736.
2. Fisher, SJ.; Roberts, JM. Lindheimer, MD.;Roberts, JM.; Cunningham, FG., editors . In: Defects in placentation and placental perfusionChelsey's Hypertensive Disorders in Pregnancy. Appleton& Lange; Stanford, CT, USA: 1999.
3. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-249.
4. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970-975.
5. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101:669-674.
6. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-1085.
7. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26:563-573.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
9. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
10. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-R1093.
11. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007;71:977-984.
12. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50:1142-1147.
13. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-26037.
14. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35; discussion 35.
15. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997;76:517-531.
16. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007;92:2672-2679.
17. Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grové D. Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG 2000;107:1258-1264.
18. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001;97:533-538.
19. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 2010;117:314-320.
20. Escudero C, Sobrevia L. A hypothesis for preeclampsia: adenosine and inducible nitric oxide synthase in human placental microvascular endothelium. Placenta 2008;29:469-483.
21. Report of the National High Blood Pressure Education Program Working Group. Report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:1-22.
22. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-192.
23. Galazios G, Papazoglou D, Giagloglou K, Vassaras G, Koutlaki N, Maltezos E. Umbilical cord serum vascular endothelial growth factor (VEGF) levels in normal pregnancies and in pregnancies complicated by preterm delivery or pre-eclampsia. Int J Gynaecol Obstet 2004;85:6-11.
24. Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patrício B, Quintanilha A, Santos-Silva A. Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors 2009;27:345-351.
25. Varughese B, Bhatla N, Kumar R, Dwivedi SN, Dhingra R. Circulating angiogenic factors in pregnancies complicated by pre-eclampsia. Natl Med J India 2010;23:77-81.
26. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res 2010;33:561-567.
27. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-1274.
28. Zhao W, Qiao J, Zhang Q, Zhao Y, Chen Q. Levels of antiangiogenic factors in preeclamptic pregnancies. Growth Factors 2010;28:293-298.
29. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52:402-407.
30. Srinivas SK, Larkin J, Sammel MD, Appleby D, Bastek J, Andrela CM, Ofori E, Elovitz MA. The use of angiogenic factors in discriminating preeclampsia: are they ready for prime time? J Matern Fetal Neonatal Med 2010;23:1294-1300.
31. Salama RH, Fathalla MM, Mekki AR, Elsadek Bel-K. Implication of umbilical cord in preeclampsia. Med Princ Pract 2011;20:124-128.
32. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with α methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS ONE 2008;3:e2766.
33. Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368-1374.
34. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
35. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008;102:146-151.
36. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009;29:464-470.